Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities

References

• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. pp 285–288.
   Google Scholar
• Kim TM, Lee SY, Jeon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008;19:1477–1484.
   PubMed Web of Science ®Google Scholar
• Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci 2009;100: 2242–2248.
   PubMed Web of Science ®Google Scholar
• Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer 2005;41:1402–1408.
   PubMed Web of Science ®Google Scholar
• Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106: 3785–3790.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216–221.
   PubMed Web of Science ®Google Scholar
• Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/+ radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006;47:1274–1282.
   PubMed Web of Science ®Google Scholar
• Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy—result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003;42:779–783.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016–1020.
   PubMed Web of Science ®Google Scholar
• Deutsch YE, Tadmor T, Podack ER, et al. CD30: an important new target in hematologic malignancies. Leuk Lymphoma 2011;52: 1641–1654.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 2013;121:2715–2724.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812–1821.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248–255.
   PubMed Web of Science ®Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119:6379–6381.
   PubMed Web of Science ®Google Scholar
• Gaal K, Sun NC, Hernandez AM, et al. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000;24:1511–1517.
   PubMed Web of Science ®Google Scholar
• Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001;19:2179–2188.
   PubMed Web of Science ®Google Scholar
• Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: a clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol 2004;12:375–387.
   PubMed Web of Science ®Google Scholar
• Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000;89:2106–2116.
   PubMed Web of Science ®Google Scholar
• Li T, Zhang B, Ye Y, et al. Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas. Hum Pathol 2006;37:54–60.
   PubMed Web of Science ®Google Scholar
• Lu D, Lin CN, Chuang SS, et al. T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute. Leuk Lymphoma 2004;45:923–928.
   PubMed Web of Science ®Google Scholar
• Schwartz EJ, Molina-Kirsch H, Zhao S, et al. Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: an analysis of 84 cases. Am J Clin Pathol 2008;130:343–351.
   PubMed Web of Science ®Google Scholar
• Hong J, Park S, Baek HL, et al. Tumor cell nuclear diameter and CD30 expression as potential prognostic parameter in patients with extranodal NK/T-cell lymphoma, nasal type. Int J Clin Exp Pathol 2012;5:939–947.
   PubMedGoogle Scholar
• Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013;98:e81–e82.
   PubMed Web of Science ®Google Scholar
• Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16:888–897.
   PubMed Web of Science ®Google Scholar
• Vaklavas C, Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012;3:209–225.
   PubMedGoogle Scholar
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496–5504.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006;17:123–130.
   PubMed Web of Science ®Google Scholar
• Bisig B, de Reynies A, Bonnet C, et al. CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. Haematologica 2013;98:1250–1258.
   PubMed Web of Science ®Google Scholar
• Kanemitsu N, Isobe Y, Masuda A, et al. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell lymphoma, nasal type (ENKL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL. Clin Cancer Res 2012;18:2164–2172.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang B, Ma X, et al. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type. Jpn J Clin Oncol 2009;39:418–424.
   PubMed Web of Science ®Google Scholar
• Hsu PL, Hsu SM. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma. Lab Invest 2000;80:1111–1119.
   PubMed Web of Science ®Google Scholar
• Muta H, Boise LH, Fang L, et al. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000;165: 5105–5111.
   PubMed Web of Science ®Google Scholar
• Paik JH, Jeon YK, Go H, et al. Extranodal NK/T cell lymphoma accompanied by heavy eosinophilic infiltration and peripheral blood eosinophilia, involving skeletal muscles. Korean J Pathol 2011; 45:S70–S74.
   Google Scholar
• Min HS, Hyun CL, Paik JH, et al. An autopsy case of aggressive CD30 + extra-nodal NK/T-cell lymphoma initially manifested with granulomatous myositis. Leuk Lymphoma 2006;47:347–352.
   PubMed Web of Science ®Google Scholar